Please Wait...

John Burns

Main profile

John Burns
Supervisor, IRT Project Management

John has nearly 10 years of experience in the pharmaceutical industry with a focus on IRT project management.  As a BioClinica Senior IRT Project Manager, John leads clinical studies through study closeout, having responsibility for issue management and overall study management.  A member of the BioClinica Trident IRT team since 2013, John brings experience from both the Sponsor and vendor perspectives, including IT management and IRT systems.  John has a Bachelor's degree in Mediated Communication from Rutgers University.

Blogs

Final installment in a three-part series on drug supply shortages in clinical trials with BioClinica's Trident IRT Team.

If you've been following this blog series on drug shortages, you know why it's so important to stay on top of clinical trial drug supply and the potential impact on clinical trials when shortages do occur: subject loss, lowered enrollment, budget escalation, delays and even study discontinuation.

In this blog, we'll see where drug shortages create impacts and what some of the most common root causes are. Coming soon in Part 3 in this series, I'll share some real-life examples of trials where BioClinica was called into rescue mode. So stay tuned and you may pick up some tips to steer clear of drug shortages in your own program.

John Burns, a member of BioClinica's Trident IRT team, was asked to present on drug shortages in clinical trials as part of a panel discussion at DIA. In it, he outlined examples of preventable causes and shared case studies showing what happens when things go awry.  Here is Part 1 in a three-part blog series recapping his discussion.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Outsourcing to #CROs? Top 5 Reasons to Consider Bringing CTMS & Quality Management/RBM Systems in House @bioclinica https://t.c…
bioclinica (9 hours ago)
Webinar tom! Take a fresh look at in-house vs. outsourced #CTMS & #RBM systms via case studies & ROI… https://t.co/cXKG3UgaGp
bioclinica (14 hours ago)
Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned. Join us at 11 AM EDT today in a live webinar.… https://t.co/1jiraT9cSL
bioclinica (Yesterday)
Still time to join us for tomorrow's webinar: Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned https://t.co/Ho13oUxdly
bioclinica (2 days ago)
ICYMI: Clean Patient Optics: helping #ClinicalResearch teams meet or beat database lock. News https://t.co/adWwISw4Cu
bioclinica (2 days ago)
Vaccine clinical trials: Boost senior participation following simple advice from Dr. Craig Curtis… https://t.co/rYg9u25vMf
bioclinica (5 days ago)

Latest Blogs: